Global Respiratory Inhaler Market is expected to reach USD 41.4 billion by 2030

Market Highlights

The Respiratory Inhaler Market is anticipated to reach USD 41.4 billion by 2030 at a 4.90 % CAGR during the forecast period 2022-2030. Respiratory inhalers are the devices which are used to control the respiratory conditions by directly inhaling the drug into the respiratory tract. Over the past 50 years, inhaler devices have revolutionized the respiratory care by delivering the medicines directly into the lungs and avoiding the adverse effects caused by the other modes of medication. However there has been a point of concern for the doctors whether the patients are talking the medication correctly or not. Because, even if you have the most potent drug in the inhaler; if the patient does not take the medication correctly and on time, you will not see the desired effect of the drug. Different inhaler drugs are being developed for the different conditions and the inhalers are prescribed to the patients on the basis of the condition of the patient and the severity of the disease. There are some major factors that are driving the market growth such as rising prevalence of respiratory disorders due to increase pollution and unhealthy lifestyle, increasing usage of combination therapies due to associated benefits such as more reliable in complex patients, increased efficacy and easy reimbursement policies associated with them and others.

On the other hand, there are some hindering factors which are restricting the market growth such as side effects and complications during inhalation, high prices of devices, and lack of accuracy etc. The market is expected to show large opportunities in the coming future with the advancement of technology in developing countries and new products with increased accuracy. However, some of the challenges which the market is expected to face includes competition from new entrants or big pharmaceutical giants entering the business or market and the continuous advancements in the product.

Global Respiratory Inhaler Market Players:

The major participants of this market are Adherium limited, AstraZeneca, Boehringer Ingelheim GmbH, Chiesi Farmaceutici S.p.A., GSK plc, Propeller Health, and Teva Pharmaceutical Industries Ltd.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Respiratory Inhaler Market Research Report

Regional Analysis:

Depending on geographic region, Respiratory Inhaler market is segmented into four key regions: North America, Europe, Asia Pacific, and Middle East & Africa. Globally North America is the largest market for Respiratory Inhalers. The North America market for Respiratory Inhalers is expected to reach at USD 11,949.4 million by the end of the forecasted period. Europe is the second-largest market for respiratory inhalers which is expected to grow at a CAGR of 6.4%. Asia pacific region is expected to be fastest growing region in respiratory Inhaler market. Middle East & Africa is expected to have limited but steady growth in the market.

Segmentation:

Respiratory Inhalers market has been segmented on the basis of type which comprises of manually operated, digitally operated. Manually operated inhalers accounted for the largest market share of the total market in 2016. On the basis of product, the market is segmented into dry powder inhaler, metered dose inhaler, and others. Dry powder inhalers accounted for the largest market share in 2016. On the basis of application, market is segmented into asthma, COPD, and other. Asthma segment accounted for the largest market share of the total market in 2016. On the basis of end user, market is segmented into hospitals & clinics, respiratory care center, and other. Hospitals & clinics dominated the global market with the largest market share of the total market in 2016.